dMed-Clinipace Raises $50 Million for China-US Clinical CRO Operations
publication date: Jul 7, 2021
dMed-Clinipace, a China-US full-service clinical CRO, completed a $50 million Series C+ financing. In April of this year, dMed and Clinipace announced their merger, which created a global company offering CRO services for oncology and rare diseases, with expertise in clinical development, regulatory, pharmacovigilance and clinical analytics. The C+ round, which will help finance the merger, was led by Springhill Fund, with contributions from Rock Springs Capital and Superstring Capital. d-Med is headquartered in Shanghai and Clinipace in North Carolina. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.